Article info

Download PDFPDF

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

Authors

  1. Correspondence to Dr Walter Fiedler; fiedler{at}uke.uni-hamburg.de
View Full Text

Citation

Fiedler W, Cresta S, Schulze-Bergkamen H, et al
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

Publication history

  • Received December 1, 2017
  • Revised December 23, 2017
  • Accepted December 26, 2017
  • First published February 1, 2018.
Online issue publication 
February 01, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.